A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

NCT00862524 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Pancreatic Cancer

Interventions

DRUG: ARRY-334543, EGFR/ErbB2 inhibitor; oral
DRUG: Gemcitabine, nucleoside analogue; intravenous

Sponsor

Array BioPharma